{
  "docId": "019de073-a38b-741c-ac33-1ee77869cf6c",
  "docSlug": "1556a4546991601fbfe098864d52433b",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 36,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 35,
  "notes": "The slide uses a checkmark system to highlight specific advantages of RL-007 and a few competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a38b-741c-ac33-1ee77869cf6c/25",
  "deckHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c",
  "deckJsonHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c.json",
  "deckAnchorHref": "/decks/019de073-a38b-741c-ac33-1ee77869cf6c#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.27
      },
      "kind": "table",
      "text": "Comparison table of 7 compounds across 5 attributes: Compound, Development stage, Mechanism of action, Focused on treating cognitive impairment, Potential for complimentary use with other therapies",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d84b529d-41b5-4f35-b311-4ac08d3372cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "CIAS & Schizophrenia landscape: RL-007's unique pharmacology, acute cognitive benefit and excellent tolerability differentiate it from the current standard of care available to CIAS & Schizophrenia patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cefd1043-14e3-47f3-918d-64e9ed7e88dc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "b77bb74c-db7f-4bd1-a96a-2e49f44d4d59",
      "evidence": "Comparison table of 7 compounds across 5 attributes",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "898919d5-308d-4d7d-827a-af48348624e4",
      "evidence": "The slide presents a structured grid comparing multiple entities across common attributes.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}